Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. To assess long-term risk of local tumor regrowth, we report updated organ preservation rate and oncologic outcomes of the OPRA trial (ClinicalTrials.gov identifier: NCT02008656 ). Patients with stage II/III rectal cancer were randomly assigned to receive induction chemotherapy followed by…

• A
  Amgen
• BS
  Bristol-Myers Squibb
• P
  Pfizer
• A
  AstraZeneca
• RP
  Regeneron Pharmaceuticals
• E
  Exelixis
• MT
  Mirati Therapeutics
• G
  Genentech
• I
  Ignyta
• NC
  National Cancer Institute

  Awards: T32 CA009501, R01CA182551, P30CA008748
• DS
  Daiichi Sankyo Europe